课题基金 / 基金详情

EXPERIMENTAL STUDY ON ACTION MECHANISMS OF RESISTANCE TO HORMONAL THERAPY AND OVERCOMING THIS RESISTANCE IN BREAST CANCER

EXPERIMENTAL STUDY ON ACTION MECHANISMS OF RESISTANCE TO HORMONAL THERAPY AND OVERCOMING THIS RESISTANCE IN BREAST CANCER
乳腺癌激素治疗抵抗作用机制及克服这种抵抗的实验研究
批准号:
14571166
负责人:
KUREBAYASHI Junichi
金额:
$1.79万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003

项目摘要

项目成果

KUREBAYASHI Junichi的其他基金

相似基金

相关文献

中文摘要
翻译
总结了本研究项目的成果。1)应用免疫组织化学方法研究HER1、HER2、P53在乳腺癌组织中的表达水平与复发性乳腺癌患者内分泌治疗反应的关系。HER1过表达的乳腺癌较早获得内分泌抵抗,患者预后较差。2)HER1酪氨酸激酶抑制剂吉非替尼(Gefitinib,G)在补充雌激素的条件下,增强了雌激素受体(ER)阳性的人乳腺癌细胞中抗雌激素Fulvestrant(F)的抗肿瘤作用。这是因为G协同增加了细胞周期蛋白依赖的激酶抑制因子p21的蛋白表达水平,并且这种作用导致了加性的G1-S细胞周期延迟。此外,在ER阴性和HER1和/或HER2过表达的乳腺癌细胞中,G诱导抗凋亡蛋白Bc l-2的表达水平降低,而凋亡比例增加。3)低氧细胞毒素替拉帕明和TX-402可抑制人乳腺癌细胞裸鼠移植瘤ER表达的降低。4)研究了长期缺氧诱导乳腺癌细胞中与乳腺癌恶性进展相关的各种基因表达水平的变化。在几个乳腺癌细胞系中观察到HER1表达水平的增加。此外,还观察到血管内皮生长因子家族成员和缺氧诱导因子-1α的表达水平增加。这些实验结果表明,HER1表达的增加可能在乳腺癌内分泌耐药的形成中起重要作用。此外,低氧细胞毒素或生长因子信号转导抑制剂的应用可能延缓或克服乳腺癌的内分泌抵抗。
英文摘要
Results of this study project are summarized. 1)We investigated the relationship between the expression levels of HER1,HER2,p53 in primary breast cancer tissues by immunohistochemistry and responses to endocrine therapy in patients with recurrent diseases. HER1-overexpressing breast cancers acquired endocrine-resistance earlier and provided a worse prognosis to the patients. 2)A HER1-tyrosine kinase inhibitor, gefitinib (G), enhanced an antitumor effect of an antiestrogen, fulvestrant (F), in estrogen receptor(ER)-positive human breast cancer cells under estrogen-supplemented conditions. This is because G synergistically increased a protein expression level of a cyclin-dependent kinase inhibitor, p21, and this effect resulted in an additive G1-S cell cycle retardation. Additionally, G induced a decrease in an expression level of an anti-apoptotic protein, Bcl-2, and an increase in an apoptotic fraction in ER-negative and HER1 and/or HER2-overexpressing breast cancer cells. 3)Hypoxic cytotoxins, tirapazamine and TX-402, inhibited a decrease in ER expression in tumors transplanted with human breast cancer cells into nude mice. 4)We investigated changes in expression levels of various genes, which are associated with malignant progression of breast cancer, in breast cancer cells induced by a long-term exposure of hypoxia. An increase in an expression level of HER1 was observed in several breast cancer cell lines. Additionally, an increase in mRNA expression levels of VEGF family members and HIF-1α was observed. These experimental results suggest that an increase, in HER1 expression may play an important role in the development of endocrine-resistance in breast cancer. Furthermore, it is suggested that administration of hypoxic cytotoxins or inhibitors of growth factor signal transduction may delay or overcome endocrine-resistance in breast cancer.
期刊论文(112)
专著(0)
科研奖励(0)
会议论文
Kurebayashi, J., et al.: "Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer."Breast Cancer. 11・1. 38-41 (2004)
Kurebayashi, J., et al.:“抑制 HER1 信号通路可增强乳腺癌内分泌治疗的抗肿瘤作用。”Breast Cancer 11・1 (2004)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Okubo, S., et al.: "Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antiestrogen fulvestrant --."British Journal of Cancer. 90・1. 236-244 (2004)
Okubo, S., et al.:“表皮生长因子受体酪氨酸激酶抑制剂吉非替尼(易瑞莎,ZD1839)和抗体氟维司群的附加抗肿瘤作用 --.”英国癌症杂志 90·1(2004 年)。 )
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
山本 裕: "原発乳癌に対する乳房造影MRI検査の有用性と生物学的バックグラウンドに関する検討"乳癌の臨床. 17. 132-136 (2002)
Yutaka Yamamoto:“乳腺 X 线 MRI 检查对原发性乳腺癌的有用性和生物学背景的研究”乳腺癌诊所。 17. 132-136 (2002)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kurebayashi, J.: "Endocrine-resistant breast cancer : underlying mechanisms and strategies for overcoming resistance."Breast Cancer. 10(2). 112-119 (2003)
Kurebayashi, J.:“内分泌耐药性乳腺癌:克服耐药性的潜在机制和策略。”乳腺癌。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 49 条
    Experimental research on the development of new treatment strategies for triple negative breast cancer
    • 批准号:
      23591911
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.24万
    • 财政年份:
      2011
    • 负责人:
      KUREBAYASHI Junichi
    • 依托单位:
    Fundamental research on the development of treatment for triple negative breast cancer
    • 批准号:
      20591561
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.66万
    • 财政年份:
      2008
    • 负责人:
      KUREBAYASHI Junichi
    • 依托单位:
    Establishment of a postsurgical micro-metastasis model of breast cancer and development of new postsurgical adjuvant therapies
    • 批准号:
      08671401
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.47万
    • 财政年份:
      1996
    • 负责人:
      KUREBAYASHI Junichi
    • 依托单位:
    Analysis of antiinvasive and antimetastatic effects of antimetasatic agents and cytotoxic drugs in a metastasis model of human breast cancer
    • 批准号:
      06671233
    • 项目类别:
      Grant-in-Aid for General Scientific Research (C)
    • 资助金额:
      $0.26万
    • 财政年份:
      1994
    • 负责人:
      KUREBAYASHI Junichi
    • 依托单位:
    海外基金